{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T04:06:34Z","timestamp":1762056394870,"version":"build-2065373602"},"reference-count":57,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National R&amp;D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea","award":["HA17C0042"],"award-info":[{"award-number":["HA17C0042"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>We evaluated the prognostic efficiency of the European Leukemia Net (ELN) 2017 criteria on the post-transplant outcomes of 174 patients with intermediate (INT; n = 108, 62%) or adverse (ADV) risk (n = 66, 38%) of acute myeloid leukemia; these patients had received the first allogeneic hematopoietic stem-cell transplantation (HSCT) at remission. After a median follow-up period of 18 months, the 2 year OS, RFS, and CIR after HSCT were estimated to be 58.6% vs. 64.4% (p = 0.299), 50.5% vs. 53.7% (p = 0.533), and 26.9% vs. 36.9% (p = 0.060) in the INT and ADV risk groups, respectively. Compared to the ELN 2017 stratification, pre-HSCT WT1 levels (cutoff: 250 copies\/104 ABL) more effectively segregated the post-HSCT outcomes of INT risk patients compared to ADV risk patients regarding their 2 year OS (64.2% vs. 51.5%, p = 0.099), RFS (59.4% vs. 32.4%, p = 0.003), and CIR (18.9% vs. 60.0% p &lt; 0.001). Indeed, high WT1 levels were more prominent in INT risk patients than in ADV risk patients. Notably, FLT3-ITD had the greatest impact on post-HSCT outcomes among all the ELN 2017 criteria components; patients in the FLT3-ITD mutant subgroups exhibited the worst outcomes regardless of their allelic ratios or NPM1 status compared to the pre-HSCT WT1 level of other INT and ADV risk patients.<\/jats:p>","DOI":"10.3390\/cancers14133199","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T20:47:56Z","timestamp":1656535676000},"page":"3199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9559-992X","authenticated-orcid":false,"given":"Tong-Yoon","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daehun","family":"Kwag","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Hyuk","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joonyeop","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7636-4693","authenticated-orcid":false,"given":"Gi-June","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-4136","authenticated-orcid":false,"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-8200","authenticated-orcid":false,"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yeouido St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hawn","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eunpyeong St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-3991","authenticated-orcid":false,"given":"Seung-Ah","family":"Yahng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Incheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-2050","authenticated-orcid":false,"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9442-9814","authenticated-orcid":false,"given":"Seok","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-4839","authenticated-orcid":false,"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Wook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-3366","authenticated-orcid":false,"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish acute leukemia registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: A population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.5045\/br.2020.S003","article-title":"New agents in acute myeloid leukemia (AML)","volume":"55","author":"Park","year":"2020","journal-title":"Blood Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2012.43.4738","article-title":"Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia","volume":"30","author":"Mrozek","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: Evaluation of the proposed reporting system","volume":"29","author":"Rollig","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/bloodadvances.2020001904","article-title":"Prognostic impact of the ELN 2017 risk classification in patients with AML receiving allogeneic transplantation","volume":"4","author":"Grimm","year":"2020","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3324\/haematol.2017.176107","article-title":"Haploidentical Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia: A Position Statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41409-021-01220-1","article-title":"The Chinese Hct Survey: A Non-Manipulated Haploidentical Transplantation Procedure Makes a Novel Contribution to Data Sharing within the Regional and Global Transplant Registries and to Worldwide Knowledge","volume":"56","author":"Niederwieser","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.bbmt.2018.02.003","article-title":"Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia","volume":"24","author":"Shah","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation","volume":"23","author":"Getta","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41409-018-0413-0","article-title":"Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation","volume":"54","author":"Grimm","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-021-00500-9","article-title":"Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"11","author":"Kim","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD working party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","article-title":"Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia","volume":"14","author":"Aitken","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7851414","DOI":"10.1155\/2020\/7851414","article-title":"Novel WT1 Target Genes: IL-2, IL-2RB, and IL-2RG Discovered During WT1 Silencing Using Lentiviral-Based RNAi in Myeloid Leukemia Cells","volume":"2020","author":"Dejjuy","year":"2020","journal-title":"Biomed Res. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.12181","article-title":"Leukaemia Relapse after Allogeneic Transplants for Acute Myeloid Leukaemia: Predictive Role of WT1 Expression","volume":"160","author":"Pozzi","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/bmt.2014.209","article-title":"Real-Time Assessment of Relapse Risk Based on the WT1 Marker in Acute Leukemia and Myelodysplastic Syndrome Patients after Hematopoietic Cell Transplantation","volume":"50","author":"Israyelyan","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bbmt.2016.03.005","article-title":"Wilms Tumor 1 Expression and Pre-Emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation","volume":"22","author":"Pozzi","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.exphem.2017.01.005","article-title":"Predictive Value of Pretransplantation Molecular Minimal Residual Disease Assessment by WT1 Gene Expression in FLT3-Positive Acute Myeloid Leukemia","volume":"49","author":"Candoni","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.leukres.2017.10.010","article-title":"High Prognostic Value of Pre-Allogeneic Stem Cell Transplantation Minimal Residual Disease Detection by WT1 Gene Expression in AML Transplanted in Cytologic Complete Remission","volume":"63","author":"Candoni","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/bmt.2016.318","article-title":"Impact of Wilms\u2019 Tumor 1 Expression on Outcome of Patients Undergoing Allogeneic Stem Cell Transplantation for AML","volume":"52","author":"Dulery","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2017.08.008","article-title":"Post-Remissional and Pre-Transplant Role of Minimal Residual Disease Detected by WT1 in Acute Myeloid Leukemia: A Retrospective Cohort Study","volume":"61","author":"Frairia","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbmt.2017.09.001","article-title":"Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value","volume":"24","author":"Nomdedeu","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbmt.2013.03.013","article-title":"Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia","volume":"19","author":"Yoon","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/ejh.12142","article-title":"BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: Consecutive monitoring in adult patients with core-binding-factor-positive AML","volume":"91","author":"Yoon","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bbmt.2014.11.008","article-title":"Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes","volume":"21","author":"Yoon","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-017-0404-4","article-title":"High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: A single-center cohort study","volume":"10","author":"Yoon","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.bbmt.2019.05.033","article-title":"WT1 measurable residual disease assay in patients with acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation: Optimal time points, thresholds, and candidates","volume":"25","author":"Cho","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41409-018-0383-2","article-title":"Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: A prospective clinical phase I\/II trial","volume":"54","author":"Kim","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.bbmt.2020.07.006","article-title":"Comparison of myeloablative (CyTBI, BuCy) versus reduced-intensity (FluBu2TBI400) peripheral blood stem cell transplantation in acute myeloid leukemia patients with pretransplant low WT1 expression","volume":"26","author":"Park","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1038\/bcj.2015.61","article-title":"Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length","volume":"5","author":"Kim","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"41590","DOI":"10.18632\/oncotarget.15295","article-title":"Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types","volume":"8","author":"Yoon","year":"2017","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood-2002-12-3627","article-title":"FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: Prognostic significance and relation to cellular drug resistance","volume":"102","author":"Zwaan","year":"2003","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3343\/lmo.2017.7.1.13","article-title":"Fragment analysis for detection of the FLT3-internal tandem duplication: Comparison with conventional PCR and Sanger sequencing","volume":"7","author":"Lee","year":"2017","journal-title":"Lab. Med. Online"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/s41409-021-01450-3","article-title":"An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. a CIBMTR analysis","volume":"56","author":"Jimenez","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2040620719882666","DOI":"10.1177\/2040620719882666","article-title":"Allogeneic transplant for FLT3-ITD mutated AML: A focus on FLT3 inhibitors before, during, and after transplant","volume":"10","author":"Bazarbachi","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3324\/haematol.2017.186346","article-title":"Allogeneic stem cell transplantation for FLT3 mutated acute myeloid leukemia in first complete remission: Does age really matter?","volume":"103","author":"Ciurea","year":"2018","journal-title":"Haematologica"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/bcj.2014.35","article-title":"European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"4","author":"Medeiros","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1200\/JCO.19.00321","article-title":"FLT3 Inhibitor Maintenance after Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?","volume":"37","author":"Levis","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","article-title":"Clinical Practice Recommendation on Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients with FLT3-Internal Tandem Duplication: A Position Statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication Mutation (Sormain)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib Maintenance in Patients with FLT3-ITD Acute Myeloid Leukaemia Undergoing Allogeneic Haematopoietic Stem-Cell Transplantation: An Open-Label, Multicentre, Randomised Phase 3 Trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"630429","DOI":"10.3389\/fimmu.2021.630429","article-title":"TKI Maintenance after Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis","volume":"12","author":"Gagelmann","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ejh.13692","article-title":"Post-Transplant Maintenance Therapy in Patients with FLT3-Mutated Acute Myeloid Leukemia: Real-World Treatment Patterns and Outcomes","volume":"107","author":"Griffin","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"612880","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41409-021-01269-y","article-title":"FLT3-ITDos and FLT3-ITDon\u2019ts: Navigating Maintenance Therapy in FLT3-ITD-Positive Acute Myeloid Leukemia Following Stem Cell Transplantation","volume":"56","author":"Ragon","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.bbmt.2016.03.027","article-title":"Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia","volume":"22","author":"Oran","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"603636","DOI":"10.3389\/fonc.2020.603636","article-title":"MRD tailored therapy in AML: What we have learned so far","volume":"10","author":"Ngai","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin Plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/13\/3199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:40:43Z","timestamp":1760139643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/13\/3199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":57,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cancers14133199"],"URL":"https:\/\/doi.org\/10.3390\/cancers14133199","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,6,29]]}}}